Healthcare
ByChina Dominates 70% of Global AI Drug Patents: ADC/Bispecifics Surge or Innovation Bubble?
China Leads 70% of Global AI Drug Patents: Simple Strategic Snapshot China now holds 70% of the world’s…
Merck’s First Fully AI-Designed Oncology Drug: 2027 China Approval Nears or Hype Peaks?
Merck’s January 26–March 2026 trajectory signals China will approve its first fully AI-designed compound by 2027—the world’s first…
Tsinghua’s Agent Hospital Pilots: World’s First AI Hospital or Closed Data Experiment?
Tsinghua University’s “world’s first AI Hospital” advanced public pilots February 28-March 2, 2026—deploying 42 AI agents across 300+…
DeepSeek AI Hits Hundreds of Hospitals: Pathology Revolution or Urban Elite Tool?
DeepSeek chatbot expanded to hundreds of hospitals across Shanghai, Shenzhen, and Chengdu on March 2, 2026—processing 3,000 pathology…
How Does AbbVie Pioneer Oncology Transformation While Sustaining Immunology Leadership Through 2030?
AbbVie strategically positions for multi-franchise dominance through its $59B immunology base (Skyrizi/Rinvoq offsetting Humira’s $17B erosion) while aggressively building oncology leadership via ImmunoGen Elahere acquisition ($10B…
How Does Johnson & Johnson Weaponize Oncology Supremacy for $50 Billion Revenue by 2030?
Johnson & Johnson orchestrates a “full-spectrum oncology domination” strategy across its Innovative Medicine division, positioning for #1 global oncology leadership…
